moxifloxacin has been researched along with abt 492 in 8 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (abt 492) | Trials (abt 492) | Recent Studies (post-2010) (abt 492) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 93 | 17 | 78 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Benedict, MS; Cammarata, SK; Lawrence, LE; Litwin, JS; Sun, E; Thorn, MD | 1 |
| Cammarata, S; Keedy, K; Lawrence, L; McCurdy, S; Nenninger, A; Quintas, M; Sheets, A | 2 |
| Bozkaya, D; Lodise, TP; Massey, J; Spargo, A; Tillotson, GS | 1 |
| Brown Elliott, BA; Wallace, RJ | 1 |
| Lamb, YN; Lee, A; Shirley, M | 1 |
1 review(s) available for moxifloxacin and abt 492
| Article | Year |
|---|---|
Delafloxacin: A Review in Community-Acquired Pneumonia.
Topics: Adult; Anti-Bacterial Agents; Asthma; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Pulmonary Disease, Chronic Obstructive | 2022 |
2 trial(s) available for moxifloxacin and abt 492
| Article | Year |
|---|---|
A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart; Humans; Male; Moxifloxacin; Young Adult | 2015 |
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Legionella pneumophila; Macrolides; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma pneumoniae; Pneumonia, Bacterial; Streptococcus pneumoniae; Young Adult | 2020 |
5 other study(ies) available for moxifloxacin and abt 492
| Article | Year |
|---|---|
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship | 2020 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Humans; Klebsiella pneumoniae; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Pneumonia, Bacterial; Staphylococcus aureus; Streptococcus pneumoniae | 2020 |
The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Drug Costs; Fluoroquinolones; Humans; Models, Economic; Moxifloxacin; Outpatients; Pneumonia, Bacterial | 2020 |
Comparison of
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria | 2021 |